VTVT
vTv Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.80
+1.27%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$31.28
From 52W high−25.56%
Volume72834.00
Market cap$125.73M
P/E (TTM)—
P/S (TTM)3.4x
Div yield—
Key dataSep 18, 2026
Open
$31.28
From 52W high
−25.56%
Volume
72834.00
Market cap
$125.73M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.1x
P/E (TTM)
—
RSI (14)
42.6
MomentumView details →
1D Return
+1.27%
YTD Return
−22.31%
SummaryUpdated Jun 1, 2026
vTv Therapeutics Inc. (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in High Point, North Carolina. The company operates as a subsidiary of MacAndrews & Forbes Incorporated and focuses on developing orally administered treatments primarily for diabetes and other metabolic disorders. Since its initial public offering in July 2015, vTv has been advancing a pipeline of small molecule therapeutics through various stages of clinical development, with particular emphasis on innovative approaches to treating type 1 diabetes and inflammatory conditions.
Similar companies
Latest newsMore news →